Utilizing AI to Save Lives and Cut Costs
AI CVD
®
AI-CVD® is the most comprehensive opportunistic cardiovascular and multi-system CT screening AI ever authorized by the FDA that enables physicians to identify hidden cardiometabolic risk for early intervention and personalized prevention strategies.
Detects What Humans Miss
Now FDA-Cleared
This webcast was hosted by Society of Cardiovascular Computed Tomography (SCCT). Because of SCCT Webcast's time limit, the Part 1 is hosted on SCCT's website and YouTube. The Part 2 and the Full Video of this Webcast is available Here.
HeartLung’s Medical Leadership Featured on "Cardiac Wire Show" to Discuss New AI for Opportunistic Detection of CVD in 10+ Million Chest CT Scans Every Year
Imaging Wire Interviews HeartLung’s Medical Leaders on AI-Enabled Opportunistic Osteoporosis Screening
1st Annual Conference on Integrating Early Detection of Heart and Lung Disease through Low-Dose CT
HeartLung participated in the world's first conference on integrating early detection of heart and lung disease through low-dose CT, featuring global leaders in preventive cardiology and lung cancer screening.
HeartLung is a proud sponsor of the conference.
Conference Highlight
AI-CVD®: Opportunistic Detection of CVD Biomarkers
Introducing
AutoChamber
®
AutoChamber™ is the first FDA-approved AI that received “Breakthrough” designation for enabling physicians to detect patients with enlarged cardiac chambers and left ventricular hypertrophy that are invisible to the human eye.
Every year, over 10 million chest CT scans are done in the US alone and among them many asymptomatic patients with enlarged heart chambers are missed resulting in late-stage heart failure, atrial fibrillation, stroke, and sudden cardiac death. AutoChamber™ AI can help physicians fill this gap and save many lives from preventable cardiovascular death.
Breakthrough Designation
Physicians
Healthcare Providers
